Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,566 shares of the company’s stock after selling 1,559 shares during the period. Kentucky Retirement Systems’ holdings in Moderna were worth $1,575,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Commerzbank Aktiengesellschaft FI boosted its position in shares of Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC grew its position in Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after buying an additional 96 shares in the last quarter. Claro Advisors LLC grew its position in Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares in the last quarter. McAdam LLC raised its holdings in Moderna by 1.1% in the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after acquiring an additional 117 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in shares of Moderna by 1.1% during the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after purchasing an additional 160 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is owned by company insiders.

Moderna Trading Up 7.2 %

Shares of MRNA stock opened at $39.51 on Tuesday. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock has a 50 day simple moving average of $58.56 and a two-hundred day simple moving average of $96.68. The company has a market cap of $15.20 billion, a P/E ratio of -6.79 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business earned ($1.39) earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts forecast that Moderna, Inc. will post -9.43 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MRNA shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. The Goldman Sachs Group decreased their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. TD Cowen reduced their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Finally, UBS Group decreased their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $86.33.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.